On March 26, 2021 Oasmia Pharmaceutical AB, an innovation-focused specialty pharmaceutical company reported that it will be presenting final data from the dose-escalation and dose-expansion cohorts of the Phase I trial of Cantrixil at the American Association of Cancer Research (AACR) (Free AACR Whitepaper) annual meeting which is being held virtually on April 10-15 and May 17-21 (Press release, Oasmia, MAR 26, 2021, View Source [SID1234577197]).
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
Details of the abstract and presentation are as follows:
Abstract Control Number: 5183
Title: TRX-E-002-1 in treatment-refractory ovarian cancer: Final phase 1 study results from the dose-escalation and dose-expansion cohorts
Presenter: Jermaine Coward, MBBS PhD, ICON Cancer Centre, South Brisbane, QLD, Australia
Session Title: Targeted Therapy and Ovarian Cancer Trials
Presentation Number: CT012
Presentation Type: 15-minute oral presentation
Date and Time: Sunday Apr 11, 2021 2:00 PM – 3:45 PM (U.S. ET) : Monday Apr 12, 2021 4:00 AM – 5:45 AM (Eastern Australian Time)
For more details, please access the AACR (Free AACR Whitepaper) annual meeting website online here.
Oasmia recently announced that it signed an agreement with Kazia Therapeutics, an Australian oncology-focused biotechnology company, to acquire exclusive global development rights for Cantrixil, a product candidate in development intended for the treatment of ovarian cancer.
Cantrixil consists of the active molecule, a potent and selective third generation benzopyran SMETI inhibitor named TRXE-002-01, encapsulated in a cyclodextrin. It is believed to target a wide spectrum of cancer cells, including chemotherapy-resistant tumor-initiating cells that are thought to be responsible for disease relapse. In December 2020, Kazia released the top-line results of a Phase I open-label study (NCT02903771) conducted at sites in the USA and Australia. The Phase I study met its primary endpoints, establishing clinical proof of concept, subject to further clinical evaluation and confirmation.